Efficacy Of OKT3 As Primary Therapy For Histologically Confirmed Acute Renal Allograft Rejection1

Abstract

OKT3 when utilized as first-line therapy reversed 98% of the acute rejection episodes, with a 1-year post-OKT3 graft survival of 87.5%.

Effect of Ethnicity on Outcome of Simultaneous Pancreas and Kidney Transplantation

“…An aggressive policy of kidney and pancreas biopsies should be employed when rejection is suspected so that therapy can be appropriately guided by the grade of rejection. Finally, it is important to note that although antibody therapy effectively reverses rejection, it does not eliminate subsequent rejection episodes (49). As a result, more attention will need to be focused on finding the optimal maintenance immunosuppressive regimen to prevent late episodes of recurrent rejection.…”

Induction Therapy in Renal Transplant Recipients

“…However, timing of therapy is important, as a delay in treatment following the 3 days of high-dose methylprednisolone therapy for steroid-resistant acute rejection is associated with decreased success (Tesi et al, 1993). OKT3 has also been used to treat vascular rejection episodes (Banff grade 2 or 3) (Kamath et al, 1997).…”

Early Posttransplant Care of Renal Transplant Recipients

“…Given the observation that acute rejection is associated with poor long‐term graft survival, several centers have employed OKT 3 as first‐line treatment for Banff 93 (43) grades IIA, IIB, and III acute rejection episodes. Rejection reversal rates of up to 98%, with 1 year post‐OKT 3 graft and patient survival rates of 87.5% and 95.5%, respectively, have been reported when OKT 3 was used as first‐line therapy for the treatment of acute rejection episodes (44). OKT 3 therapy can be reinstituted successfully in patients who are antibody‐negative or have a low titer (< 1 : 100) anti‐OKT 3 ‐antibody after their first course of OKT 3 .…”